title: Differential post-surgical metastasis and survival in SCID, NOD-SCID and NOD-SCID-IL-2Rγ(null) mice with parental and subline variants of human breast cancer: implications for host defense mechanisms regulating metastasis.
abstract: We compare for the first time, the metastatic aggressiveness of the parental MDA-MB-231 breast cancer cell line and two luciferase-tagged in vivo-derived and selected pro-metastatic variants (LM2-4/luc⁺ and 164/8-1B/luc⁺ in SCID, NOD-SCID and NOD-SCID-IL-2Rγ(null) (NSG) mice following orthotopic implantation and primary tumour resection. The variants are known to be more aggressively metastatic in SCID mice, compared to the parental line which has limited spontaneous metastatic competence in these mice. When 2×10⁶ cells were injected into the mammary fat pad, the growth of the resultant primary tumours was identical for the various cell lines in the three strains of mice. However, metastatic spread of all three cell lines, including the MDA-MB-231 parental cell line, was strikingly more aggressive in the highly immunocompromised NSG mice compared to both NOD-SCID and SCID mice, resulting in extensive multi-organ metastases and a significant reduction in overall survival. While these studies were facilitated by monitoring post-surgical spontaneous metastases using whole body bioluminescence imaging, we observed that the luciferase-tagged parental line showed altered growth and diminished metastatic properties compared to its untagged counterpart. Our results are the first to show that host immunity can have a profound impact on the spread of spontaneous visceral metastases and survival following resection of a primary tumour in circumstances where the growth of primary tumours is not similarly affected; as such they highlight the importance of immunity in the metastatic process, and by extension, suggest certain therapeutic strategies that may have a significant impact on reducing metastasis.
authors: Department of Medical Biophysics, University of Toronto and Biological Sciences Platform, Sunnybrook Research Institute, Toronto, Ontario, Canada. cmilsom@sri.utoronto.ca
authors: Chloe C
authors: CC
authors: Milsom
authors: Christina R
authors: CR
authors: Lee
authors: Christina
authors: C
authors: Hackl
authors: Shan
authors: S
authors: Man
authors: Robert S
authors: RS
authors: Kerbel
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002471:Cell Transformation, Neoplastic; D005260:Female; D017353:Gene Deletion; D006801:Humans; D049409:Luciferases, Firefly / Q000235:genetics; D008325:Mammary Neoplasms, Experimental / Q000235:genetics / Q000473:pathology* / Q000601:surgery*; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D060787:Neoplasm Grading; D009362:Neoplasm Metastasis; D015375:Receptors, Interleukin-2 / Q000172:deficiency* / Q000235:genetics*; D016019:Survival Analysis
chemical_list: D015375:Receptors, Interleukin-2; D049409:Luciferases, Firefly
references: Stem Cells. 1998;16(3):166-77
references: 9617892
references: Surg Oncol Clin N Am. 2001 Apr;10(2):257-69, vii-viiii
references: 11382586
references: Blood. 2002 Nov 1;100(9):3175-82
references: 12384415
references: Biomed Pharmacother. 2005 Oct;59 Suppl 2:S375-9
references: 16507413
references: Sci Transl Med. 2012 Nov 7;4(159):159ra149
references: 23136044
references: Nat Rev Cancer. 2008 Oct;8(10):755-68
references: 18784658
references: Nat Rev Cancer. 2002 Jun;2(6):442-54
references: 12189386
references: Clin Cancer Res. 2009 Aug 1;15(15):4867-74
references: 19622578
references: Mol Cancer Ther. 2010 Apr;9(4):996-1006
references: 20371722
references: Adv Immunol. 2006;90:1-50
references: 16730260
references: Int J Oncol. 2007 Oct;31(4):741-51
references: 17786304
references: Cancer Res. 2006 Apr 1;66(7):3386-91
references: 16585158
references: Nature. 2008 Dec 4;456(7222):593-8
references: 19052619
references: J Toxicol Sci. 2009 Feb;34(1):123-7
references: 19182442
references: Cancer Cell. 2009 Mar 3;15(3):232-9
references: 19249681
references: Nat Rev Cancer. 2011 Feb;11(2):135-41
references: 21258397
references: J Clin Invest. 2007 May;117(5):1175-83
references: 17476347
references: Bull Acad Natl Med. 2008 Oct;192(7):1469-87; discussion 1487-9
references: 19445369
references: Breast Cancer Res Treat. 2007 Sep;104(3):267-75
references: 17066321
references: Cancer Res. 2008 Jun 15;68(12):4500-5
references: 18559492
references: Clin Cancer Res. 2009 May 15;15(10):3277-86
references: 19447870
references: Nat Rev Cancer. 2009 Apr;9(4):239-52
references: 19279573
references: Nature. 2005 Dec 8;438(7069):820-7
references: 16341007
references: Nat Med. 1995 Feb;1(2):149-53
references: 7585012
references: Leukemia. 1998 Dec;12(12):2029-33
references: 9844934
references: Gut. 2013 Feb;62(2):259-71
references: 22543158
references: PLoS One. 2012;7(10):e47995
references: 23118918
references: Immunity. 1995 Mar;2(3):223-38
references: 7697543
references: Oncol Rep. 2005 Sep;14(3):633-7
references: 16077966
references: Nat Rev Cancer. 2006 Jan;6(1):24-37
references: 16397525
references: Photochem Photobiol Sci. 2008 Jun;7(6):675-80
references: 18528551
references: Int J Oncol. 2008 Jan;32(1):153-9
references: 18097554
references: Nat Rev Cancer. 2002 Aug;2(8):563-72
references: 12154349
references: Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S134-9
references: 14508091
references: Clin Cancer Res. 2009 Oct 15;15(20):6358-66
references: 19825954
references: J Clin Invest. 2007 May;117(5):1137-46
references: 17476343
references: Carcinogenesis. 2008 Jun;29(6):1092-5
references: 18453542
references: Annu Rev Immunol. 2009;27:83-117
references: 19007331
references: Cell. 2010 Mar 19;140(6):883-99
references: 20303878
references: Luminescence. 2007 May-Jun;22(3):221-8
references: 17286245
references: Cancer Res. 2008 Dec 15;68(24):10068-76
references: 19074872
references: Cancer Metastasis Rev. 2007 Dec;26(3-4):737-47
references: 17846863